Index
S&P 500
P/E
16.44
EPS (ttm)
9.55
Insider Own
2.28%
Shs Outstand
68.55M
Perf Week
4.64%
Market Cap
10.36B
Forward P/E
9.37
EPS next Y
16.76
Insider Trans
-65.69%
Shs Float
64.44M
Perf Month
4.61%
Enterprise Value
24.46B
PEG
0.48
EPS next Q
3.71
Inst Own
98.51%
Perf Quarter
16.56%
Income
721.80M
P/S
0.76
EPS this Y
34.23%
Inst Trans
-1.14%
Perf Half Y
31.94%
Sales
13.64B
P/B
-
EPS next Y
15.79%
ROA
4.00%
Perf YTD
38.23%
Book/sh
-9.50
P/C
13.24
EPS next 5Y
19.58%
ROE
635.30%
52W High
159.42 -1.49%
Perf Year
10.93%
Cash/sh
11.86
P/FCF
7.89
EPS past 3/5Y
18.56% 8.29%
ROIC
6.18%
52W Low
101.00 55.49%
Perf 3Y
77.51%
EV/EBITDA
8.97
Sales past 3/5Y
5.53% 3.39%
Gross Margin
27.00%
Volatility
3.94% 2.67%
Perf 5Y
28.17%
EV/Sales
1.79
EPS Y/Y TTM
-11.49%
Oper. Margin
14.74%
ATR (14)
4.46
Perf 10Y
107.09%
Quick Ratio
1.24
Sales Y/Y TTM
6.46%
Profit Margin
5.29%
RSI (14)
59.80
Current Ratio
1.29
EPS Q/Q
-5.07%
SMA20
4.02%
Beta
0.84
Debt/Eq
-
Sales Q/Q
9.87%
SMA50
3.69%
Rel Volume
2.29
Prev Close
154.08
Employees
78000
LT Debt/Eq
-
SMA200
18.06%
Avg Volume
863.16K
Price
157.04
IPO
Oct 31, 1995
Option/Short
Yes / Yes
Trades
Volume
1,997,962
Change
1.92%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-06-24 Initiated
Barclays
Equal Weight
$133
Aug-07-23 Upgrade
UBS
Neutral → Buy
$100 → $142
Nov-01-22 Downgrade
Deutsche Bank
Buy → Hold
$97 → $72
Oct-31-22 Downgrade
UBS
Buy → Neutral
$117 → $74
Aug-19-22 Resumed
UBS
Buy
$106 → $117
Jun-21-22 Reiterated
BofA Securities
Underperform
$110 → $90
Sep-10-21 Initiated
Cowen
Market Perform
$145
Aug-12-21 Downgrade
Barclays
Overweight → Equal Weight
$135 → $146
Mar-26-21 Downgrade
BofA Securities
Neutral → Underperform
$127 → $118
Jan-05-21 Downgrade
BofA Securities
Buy → Neutral
$127
Jan-24-20 Upgrade
Goldman
Neutral → Buy
$72 → $97
Nov-07-19 Downgrade
Raymond James
Outperform → Mkt Perform
Oct-25-19 Downgrade
Wolfe Research
Outperform → Peer Perform
Sep-11-19 Downgrade
William Blair
Outperform → Mkt Perform
Jul-26-19 Downgrade
Robert W. Baird
Outperform → Neutral
$70 → $65
Jan-08-19 Upgrade
UBS
Sell → Neutral
Jan-03-19 Initiated
Deutsche Bank
Buy
$60
Dec-14-18 Initiated
Barclays
Overweight
Nov-28-18 Upgrade
Raymond James
Mkt Perform → Outperform
Nov-16-18 Initiated
UBS
Sell
$64
Show Previous Ratings
May-05-26 04:05PM
Apr-20-26 02:06PM
Mar-31-26 08:06PM
Mar-18-26 03:00PM
Mar-06-26 11:49AM
12:40PM
Loading…
Mar-05-26 12:40PM
Mar-04-26 11:30AM
10:08AM
Mar-03-26 06:56PM
Feb-27-26 04:48AM
04:03AM
03:50AM
Feb-24-26 02:00PM
09:40AM
02:53AM
09:40AM
Loading…
Feb-23-26 09:40AM
Feb-20-26 09:50AM
04:09AM
Feb-19-26 09:20AM
05:30AM
04:34AM
Feb-17-26 04:53PM
Feb-13-26 10:24AM
Feb-12-26 11:03AM
10:54AM
10:41AM
09:25AM
Feb-11-26 09:15AM
Feb-10-26 12:30PM
09:32AM
10:38AM
Loading…
Feb-09-26 10:38AM
08:50AM
12:31AM
Feb-05-26 09:40AM
09:40AM
Feb-04-26 07:55PM
(Morningstar Research)
+5.44%
02:54PM
10:59AM
Feb-03-26 06:03PM
(The Wall Street Journal)
+21.17%
04:26PM
01:18PM
12:38PM
12:25PM
11:45AM
11:16AM
11:14AM
10:23AM
09:59AM
09:40AM
(The Wall Street Journal)
08:10AM
05:54AM
12:01AM
Feb-02-26 09:55PM
08:40PM
06:38PM
05:20PM
04:20PM
04:05PM
03:00PM
Jan-31-26 10:01PM
Jan-30-26 11:56AM
Jan-29-26 11:34PM
Jan-27-26 06:00PM
Jan-21-26 06:15PM
10:00AM
Jan-19-26 12:31PM
Jan-16-26 01:56PM
04:25AM
Jan-15-26 10:34AM
Jan-14-26 11:50AM
Jan-13-26 06:00PM
Jan-07-26 06:00PM
06:00AM
Jan-02-26 09:32AM
Dec-29-25 08:53AM
01:30AM
Dec-23-25 09:02AM
Dec-22-25 06:00PM
09:14AM
Dec-19-25 09:13AM
Dec-18-25 09:07AM
Dec-15-25 09:05AM
Dec-11-25 08:00AM
Nov-28-25 11:30AM
Nov-24-25 11:49AM
Nov-14-25 04:53PM
04:16PM
Nov-13-25 10:31PM
Nov-12-25 01:11PM
Nov-10-25 06:41AM
Nov-05-25 12:38AM
Nov-04-25 08:00AM
Nov-02-25 01:07PM
Oct-30-25 07:39PM
(Morningstar Research)
-6.17%
01:59PM
01:35AM
Oct-29-25 05:25PM
05:25PM
04:05PM
Oct-28-25 11:27AM
DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BERKSHIRE HATHAWAY INC 10% Owner May 01 '26 Sale 149.84 1,220,376 182,864,679 28,880,209 May 05 06:52 PM Waters Kathleen Alyce Chief Legal & Pub. Affairs Off Feb 06 '26 Option Exercise 108.93 8,079 880,045 105,833 Feb 09 06:57 PM ACKERMAN JOEL CFO and Treasuer Feb 06 '26 Option Exercise 108.93 44,065 4,800,000 185,705 Feb 09 06:56 PM BERKSHIRE HATHAWAY INC 10% Owner Jan 29 '26 Sale 120.56 1,658,480 199,939,881 30,100,585 Feb 02 05:30 PM HEARTY JAMES O Chief Compliance Officer Dec 04 '25 Option Exercise 108.93 5,875 639,964 31,913 Dec 05 04:35 PM BERKSHIRE HATHAWAY INC 10% Owner Oct 27 '25 Sale 135.36 401,514 54,347,249 31,759,065 Oct 29 06:09 PM BERKSHIRE HATHAWAY INC 10% Owner Jul 31 '25 Sale 140.61 1,635,962 230,024,764 32,160,579 Aug 04 09:00 PM HEARTY JAMES O Chief Compliance Officer Jul 23 '25 Sale 150.00 2,351 352,650 26,038 Jul 24 08:34 PM HEARTY JAMES O Officer Jul 23 '25 Proposed Sale 150.00 2,351 352,650 Jul 23 04:05 PM BERKSHIRE HATHAWAY INC 10% Owner May 27 '25 Sale 139.45 103,274 14,401,483 33,796,541 May 27 09:34 PM BERKSHIRE HATHAWAY INC 10% Owner May 23 '25 Sale 137.81 64,066 8,828,933 33,899,815 May 27 09:34 PM BERKSHIRE HATHAWAY INC 10% Owner May 22 '25 Sale 138.98 32,660 4,538,983 33,963,881 May 27 09:34 PM BERKSHIRE HATHAWAY INC 10% Owner May 08 '25 Sale 147.11 1,145,938 168,576,647 33,996,541 May 12 04:05 PM